FLUORODOPA F18
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLUORODOPA F18 (FLUORODOPA F18).
Fluorodopa F18 is a radioactive diagnostic agent that is taken up by dopaminergic neurons in the striatum and converted by aromatic L-amino acid decarboxylase to fluorodopamine, which is stored in presynaptic vesicles. The emitted positrons allow for PET imaging to assess functional integrity of the nigrostriatal dopaminergic system.
| Metabolism | Metabolized by aromatic L-amino acid decarboxylase (AAAD) to fluorodopamine and by catechol-O-methyltransferase (COMT) to 3-O-methylfluorodopa. |
| Excretion | Primarily renal excretion; approximately 70-80% of the injected dose is excreted unchanged in urine within 2 hours, with the remainder eliminated via biliary/fecal routes (<5%). |
| Half-life | 110 minutes (physical half-life of F-18); biological half-life is approximately 2-3 hours, allowing imaging up to 4-6 hours post-injection. |
| Protein binding | Not significantly bound to plasma proteins; <5% bound. |
| Volume of Distribution | Approximately 0.5-1.0 L/kg, reflecting distribution into total body water and tissues. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: Uptake in striatal tissue occurs rapidly; peak brain uptake by 30-60 minutes post-injection. |
| Duration of Action | Imaging window of 60-90 minutes post-injection for optimal PET acquisition; clinical interpretation feasible within 3-4 hours. |
185-370 MBq (5-10 mCi) intravenous bolus injection for positron emission tomography imaging. Administered once per imaging session.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for any degree of renal impairment. Renal excretion is negligible. |
| Liver impairment | No dose adjustment required for hepatic impairment. Drug is not metabolized by the liver. |
| Pediatric use | Weight-based dosing: 3.7 MBq/kg (0.1 mCi/kg) with a minimum dose of 37 MBq (1 mCi) and maximum of 185 MBq (5 mCi) intravenously. |
| Geriatric use | No specific dose adjustment needed; use same dosing as for younger adults. Consider lower end of dose range if patient is frail or has reduced lean body mass. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FLUORODOPA F18 (FLUORODOPA F18).
| Breastfeeding | Not recommended in breastfeeding due to radiation exposure. M/P ratio not available. Discontinue breastfeeding for 24 hours after administration if used, or pump and discard. |
| Teratogenic Risk | Fluorodopa F18 is a radiopharmaceutical. Radiation exposure exceeds 0.5 mGy/MBq to uterus in early pregnancy. First trimester risk of congenital anomalies increased; organogenesis period highest risk. Second and third trimester risks include growth restriction, neurodevelopmental effects. Fetal thyroid absorbs iodine-131 if metabolite. Not recommended in pregnancy unless benefit outweighs radiation risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to fluorodopa F18 or any component of the formulation"]
| Precautions | ["Radiopharmaceuticals should be used with caution in patients with known hypersensitivity to the active substance or any of the excipients.","Exposure to ionizing radiation is associated with increased risk of cancer. Use the smallest dose necessary to obtain adequate imaging.","Potential for interference with drugs affecting dopaminergic system (e.g., carbidopa, entacapone). Adjust medications accordingly."] |
| Food/Dietary | No specific food restrictions. Avoid high-protein meals within 4 hours of injection as they may alter dopamine metabolism. Caffeine and alcohol are not known to interact significantly but should be avoided per routine pre-scan protocols. |
Loading safety data…
| Fetal Monitoring | Monitor maternal urinary excretion and hydration. No specific fetal monitoring recommended; confirm negative pregnancy test before administration. Post-procedure radiation safety instructions; avoid close contact with pregnant women and infants for 24 hours. |
| Fertility Effects | Radiation dose to gonads may reduce fertility with repeated exposure; theoretical risk of ovarian testicular damage. No specific fertility studies available. |
| Clinical Pearls | Fluorodopa F18 is a radiopharmaceutical used in PET imaging to evaluate dopaminergic function in suspected Parkinson's disease. Administer via IV injection over 2 minutes; image acquisition starts 60-90 minutes post-injection. Ensure patient has not taken carbidopa or other dopaminergic medications for at least 12 hours prior to study to avoid interference. Hydrate patient before and after administration to promote renal clearance of unbound tracer. Common adverse effects include transient injection site pain and headache. |
| Patient Advice | This is an imaging drug that helps evaluate dopamine function in your brain. · You will receive a small amount of radiation; benefits outweigh risks. · Avoid taking Parkinson's medications (e.g., carbidopa-levodopa) for 12 hours before the scan unless directed otherwise. · Drink plenty of water before and after the procedure to flush the drug out of your body. · The injection may sting briefly; after the scan, you can resume normal activities. |